NASDAQ:BCLI Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis $0.64 +0.03 (+4.10%) As of 08/7/2025 03:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BCLI alerts:Sign Up Key Stats Today's Range$0.59▼$0.6450-Day Range$0.58▼$1.3152-Week Range$0.52▼$6.00Volume16,731 shsAverage Volume653,341 shsMarket Capitalization$7.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Read More Brainstorm Cell Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreBCLI MarketRank™: Brainstorm Cell Therapeutics scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Brainstorm Cell Therapeutics.Read more about Brainstorm Cell Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($3.01) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainstorm Cell Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainstorm Cell Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Brainstorm Cell Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.14% of the float of Brainstorm Cell Therapeutics has been sold short.Short Interest Ratio / Days to CoverBrainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainstorm Cell Therapeutics has recently decreased by 6.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBrainstorm Cell Therapeutics does not currently pay a dividend.Dividend GrowthBrainstorm Cell Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.66 Percentage of Shares Shorted3.14% of the float of Brainstorm Cell Therapeutics has been sold short.Short Interest Ratio / Days to CoverBrainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainstorm Cell Therapeutics has recently decreased by 6.30%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest4 people have searched for BCLI on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Brainstorm Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.15% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.Read more about Brainstorm Cell Therapeutics' insider trading history. Receive BCLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCLI Stock News HeadlinesMaxim Group Downgrades Brainstorm Cell Therapeutics (BCLI)July 24, 2025 | msn.comBrainstorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQBJuly 18, 2025 | finanznachrichten.deIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. | Brownstone Research (Ad)Brainstorm Cell Therapeutics Faces Nasdaq Delisting NoticeJuly 18, 2025 | msn.comBrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQBJuly 17, 2025 | prnewswire.comBrainstorm Cell Therapeutics Inc. BCLI (U.S.: Nasdaq) - The Wall Street ...July 16, 2025 | wsj.comBrainStorm Cell Therapeutics Inc.: FDA Review of Citizen Petition Offers a Fresh Look at NurOwn's Evidence of Treatment EffectivenessJuly 8, 2025 | finanznachrichten.deFDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment EffectivenessJuly 8, 2025 | prnewswire.comSee More Headlines BCLI Stock Analysis - Frequently Asked Questions How have BCLI shares performed this year? Brainstorm Cell Therapeutics' stock was trading at $2.27 at the beginning of the year. Since then, BCLI stock has decreased by 72.0% and is now trading at $0.6350. How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) posted its earnings results on Thursday, May, 15th. The biotechnology company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.07. Read the conference call transcript. When did Brainstorm Cell Therapeutics' stock split? Brainstorm Cell Therapeutics's stock reverse split before market open on Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Brainstorm Cell Therapeutics' major shareholders? Top institutional investors of Brainstorm Cell Therapeutics include Gunderson Capital Management Inc. (0.26%). Insiders that own company stock include Chaim Lebovits, Stacy Lindborg and Ibrahim B Dagher. View institutional ownership trends. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include CocaCola (KO), Organovo (ONVO), Cardium Therapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Protalix BioTherapeutics (PLX) and Isoray (ISR). Company Calendar Last Earnings5/15/2025Today8/08/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCLI CIK1137883 Webwww.brainstorm-cell.com Phone(201) 488-0460FaxN/AEmployees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.62 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-519.50% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.36) per share Price / Book-0.47Miscellaneous Outstanding Shares11,035,000Free Float8,742,000Market Cap$7.01 million OptionableOptionable Beta0.12 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:BCLI) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.